Candriam S.C.A. Reduces Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Candriam S.C.A. lowered its position in Immunocore Holdings plc (NASDAQ:IMCR) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 134,785 shares of the company’s stock after selling 5,221 shares during the quarter. Candriam S.C.A. owned 0.27% of Immunocore worth $3,976,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP increased its position in shares of Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock valued at $219,430,000 after buying an additional 668,382 shares in the last quarter. FMR LLC increased its position in shares of Immunocore by 0.5% in the third quarter. FMR LLC now owns 4,836,040 shares of the company’s stock valued at $150,546,000 after buying an additional 23,436 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after buying an additional 520,950 shares in the last quarter. Bellevue Group AG increased its position in shares of Immunocore by 4.4% in the third quarter. Bellevue Group AG now owns 1,205,464 shares of the company’s stock valued at $37,526,000 after buying an additional 50,810 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in shares of Immunocore by 65.6% in the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock valued at $23,587,000 after buying an additional 300,200 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on IMCR. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Friday, February 28th. Mizuho lowered Immunocore from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $72.00 to $38.00 in a research note on Monday, November 11th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 price objective on shares of Immunocore in a research note on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Stock Down 3.3 %

Shares of NASDAQ:IMCR opened at $29.80 on Friday. The stock’s 50-day moving average price is $30.16 and its two-hundred day moving average price is $31.60. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 12-month low of $27.69 and a 12-month high of $66.00. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -31.37 and a beta of 0.79.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.